Clinical trials: Cancer Cachexia Syndrome
Cancer Cachexia, Atypical Anorexia Nervosa
Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients
The main purpose in the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) is to prolong life and to improve quality of life (QoL) as far as possible.
- Trial name
- NCT02359123
- Testing
- Cannabics capsules
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Cannabics Pharmaceuticals Inc.
Cachexia; Cancer, Cachexia
OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of the OLE study is to evaluate the long-term safety and tolerability of rilogrotug treatment in participants who have completed the parent study and are eligible to receive continued treatment.
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH-OLE (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 400 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Cachexia-Anorexia Syndrome, Solid Tumor Malignancies
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia
This is a clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SXRN Injection in cancer patients with anorexia-cachexia.
- Trial name
- NCT07231120
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Cachexia-Anorexia Syndrome, Cachexia; Cancer
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia.
- Trial name
- NCT07890324
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Jiangsu Guiqiong Pharmaceutical Co., Ltd.
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Cancer Cachexia, Cancer Cachexia Syndrome
The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia
Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia
- Trial name
- NCT07735104
- Testing
- QLS2319
- Where
- 2 sites in China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.